Lead Candidate

A FULLY HUMAN NEUROPROTECTIVE ANTIBODY

  • Contains Influential Antibody Sequence Motifs

    Identified using the AGS technology confirming critical disease-associated antibody somatic hypermutations

  • Neuronal Specificity

    Exhibits specific binding to neuronal cells and tissues in both animals and humans

  • Preclinical Efficacy

    Demonstrated neuroprotective capabilities in-vitro and a consistent reduction in disability within preclinical models of neurologic disease validated in blinded third-party studies

  • Crosses the BBB and Enters Cortical Motor Neurons

    In a healthy WT model was able to cross the BBB and internalize across multiple layers of cortical neurons

  • Target Identification and Verification

    Unique target identified, verified, and proven colocalization with intercellular stress management machinery

  • Broad Neuroprotective Impact

    Broad neuroprotective capabilities, with proof-of-concept in MS and planned expansion into ALS

  • Patent Achievement

    A US patent has been issued for TGM-010 mAb and its fragments; claims for indicational therapeutic use will be pursued next

GenrAb’s Growing Pipeline

  • Stage 1

    Screening for AGS sequence and neuronal binding

  • In-vitro efficacy and toxicity analysis

    Stage 2

  • Stage 3

    Efficacy validated in multiple preclinical models

  • Identify and verify molecular target

    Stage 4

  • Stage 5

    Determine target biology and therapeutic MoA

  • mAbs optimized for dosing

    Stage 6

© 2026 GenrAb. All Rights Reserved.